Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

By afschroeder • November 27, 2025

Khanna D, Spino C, Tashkin DP, Bernstein EJ, Goldin J, Kleerup EC, Harui A, Ibrahim G, Kim GHJ, Huang S, McLain R, Tu YH, Nagaraja V, Silver RM, Steen VD, Weigt SS, Lee JS, Fischer A, Scholand MB, Gordon JK, Dellaripa PF, Rosas IO, Hunninghake GM, Trojanowski MA, Simms RW, Dematte JE, Hsu VM, Domsic RT, Raghu G, Mayes MD, Boente RD, Roth MD; Scleroderma Lung Study III Investigators. Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. ACR Open Rheumatol. 2025 Dec;7(12):e70126. doi: 10.1002/acr2.70126. PMID: 41294296; PMCID: PMC12648624.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults

Sisliyan C, Andres JT, Keyashian K. Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults. Dig Dis Sci. 2026 Aug 9.[...]

Staff Perspectives on Optimising Organisational Responses to Patient-Initiated Workplace Violence

Cannedy S, Lesser R, Yano EM, Hamilton AB, Fenwick KM. Staff Perspectives on Optimising Organisational Responses to Patient-Initiated Workplace Violence. J Adv Nurs. 2026 Aug[...]

Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration

Ghassemi S, Singh JA, Jiang R, Young-Xu Y, Cunningham FE, Glassman PA, Zhao X, Salone C, Au A, Miller DR, Her Q, Dong D, Aspinall[...]